Investigators conducted sought to determine the efficacy of artemether-lumefantrine against Plasmodium falciparum and if treatment outcomes are linked to genetic traits in the Pfkelch13 alleles.
Quantitative MRI with brain volume assessment and ADC histogram analyses were performed for the first time in 65 patients with cerebral malaria to compare disease signatures of children and adults as well as fatal and nonfatal cases.
Children hospitalized with severe anemia where malaria is endemic have a high risk of readmission and death within 6 months after discharge.
This retrospective study aims to shed light on the relationship between splenic infarction and infection.
Disruption to services for HIV, tuberculosis, and malaria due to COVID-19 could lead to considerable loss of life in low- and middle-income countries.
Surface accumulation of parasite histones may be linked to coagulation activation and blood-brain barrier breakdown in children with cerebral malaria.
Arakoda (tafenoquine; 60 Degrees Pharmaceuticals) has been made available in the US for the prevention of malaria in patients aged ≥18 years.
For patients with normal glucose-6-phosphate dehydrogenase activity in malaria-endemic areas where frequent relapsing strains of Plasmodium vivax are prevalent, a 7-day high-dose course of primaquine was noninferior to a 14-day course.
Eli Lilly was the only pharmaceutical company providing quinidine gluconate in the United States, but in November 2017 it stopped manufacturing the drug and the remaining supplies expired.
In patients with malaria who have normal levels of glucose-6-phosphate dehydrogenase, 7-day primaquine was well tolerated and noninferior to 14-day primaquine.
